In contrast, the inclusion criteria of the TheraP trial, which compared [177Lu]Lu-PSMA-617 with cabazitaxel, referred to the maximum standardized uptake value (SUVmax) of the tumor lesions and included a second PET/CT scan using [18F]Fluorodeoxyglucose (FDG). The gene discussed is FOLH1; the disease is neoplasm.